Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

1444 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The conceptual hypothesis of this study is that primary angioplasty is superior to a combined strategy of immediate thrombolysis followed by routine angioplasty in patients with ST-segment elevation acute myocardial infarction (STEMI), even with the inherent delay of the transfer of these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Revascularization StrategIes for ST Elevation Myocardial Infarction Trial

NCT03263468

ST Elevation Myocardial Infarction Coronary Stenting Primary Angioplasty

UNKNOWN NA

The Thrombus Aspiration During PCI After Thrombolysis in STEMI

NCT06654453

ST-segment Elevation Myocardial Infarction

NOT_YET_RECRUITING NA

Thrombus Aspiration in Patients With STEMI

NCT02606435

ST-segment Elevation Myocardial Infarction

UNKNOWN PHASE4

Adjunctive, Low-dose tPA in Primary PCI for STEMI

NCT03335839

Myocardial Infarction Percutaneous Coronary Intervention

COMPLETED PHASE3

Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction

NCT02164695

ST-segment Elevation Myocardial Infarction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, multicenter, open-label clinical trial comparing two strategies of reperfusion in STEMI. Patients will be randomly allocated to: primary angioplasty or post-thrombolysis angioplasty. A clinical follow-up will be performed at 12 months. In this trial, 1444 patients with STEMI will be randomized to primary angioplasty with immediate stent implantation in at least the infarct related artery (IRA) under bivalirudin protection, or to a combined strategy of immediate thrombolysis with tenecteplase (TNK) and enoxaparin followed by cardiac catheterization and adequate revascularization when indicated during the next morning after randomization.

Primary endpoint:

To compare the clinical efficacy (incidence of the composite endpoint formed by death, reinfarction, new revascularization, rehospitalization or severe hemorrhage within 12 months) of primary angioplasty versus thrombolytic treatment followed by percutaneous coronary intervention (PCI) the next day in patients with STEMI.

Secondary endpoints:

* Components of the composite endpoint individually analysed at 12 months (death, reinfarction, new revascularization, rehospitalization and severe hemorrhage).
* Cardiovascular mortality and its different components (pre-specified in the case report forms, CRF) at 12 months.
* Incidence of the composite endpoint formed by death, reinfarction, new revascularization, rehospitalization and/or hemorrhage at 30 days.
* Incidence of major bleeding events during hospitalization and at 30 days.
* To compare the clinical efficacy of both treatments according to the timing of presentation after symptom onset (0 to 3 hours, \>3-6 hours, and \>6-12 hours), to the patient´s age (\> or \< 75 years), to the infarction localization (anterior or inferior), to gender (male or female), to the presence of diabetes mellitus and to the characteristics of the recruiting center (with or without 24-hour catheterization facilities).
* Incidence of the composite endpoint formed by death, reinfarction, new revascularization, rehospitalization and/or hemorrhage at 3 years.
* Components of the composite endpoint individually analysed at 3 years (death, reinfarction, new revascularization, rehospitalization and severe hemorrhage).
* Analysis of stent thrombosis according to the Academic Research Consortium (ARC) definition (http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4253t2.rtf.) within 30 days, 12 months and 3 years.
* To compare the combination of death, reinfarction, revascularization, rehospitalization and/or major hemorrhage of patients treated with primary angioplasty versus those assigned to the postrombolysis angioplasty who underwent catheterization the following day within 30 days, 12 months and 3 years.
* To compare every indivicual components of the combine endpoint (death, reinfarction, revascularization, rehospitalization and major hemorrhage) of patients treated with primary angioplasty versus those assigned to the postrombolysis angioplasty who underwent catheterization the following day within 30 days, 12 months and 3 years.
* To compare the cost-effectiveness relationship (cost of maintaining a patient alive and without adverse cardiovascular events within the first year post-infarction) of both strategies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Primary angioplasty

Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations

Group Type ACTIVE_COMPARATOR

Reperfusion strategies

Intervention Type OTHER

Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty

Post-thrombolysis angioplasty

Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering \>50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization

Group Type ACTIVE_COMPARATOR

Reperfusion strategies

Intervention Type OTHER

Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Reperfusion strategies

Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years
* Chest discomfort \> 30 minutes with no response to nitroglycerin
* Time from the onset of symptoms to randomization between 0 and 12 hours
* ST segment elevation \> 1 mm in two or more contiguos precordial leads or non-diagnostic ECG (left bundle branch block or pacemarker rhythm) with classic symptoms.
* Killip class equal or less than 3
* Written informed consent

Exclusion Criteria

* Cardiogenic shock defined as a systolic blood pressure \<90 mm Hg without response to fluid administration or \<100 mm Hg in patients with supportive treatment and no bradycardia
* Suspicion or evidence of mechanical complications of STEMI
* Non-cardiac disease that is likely to jeopardize compliance with follow-up schedule of the study (life expectancy \< 1 year)
* woman of childbearing potential unless a negative pregnant test
* Major contraindications for thrombolytic therapy
* Participation in other trial
* Known multivessel disease identified as unsuitable for revascularization
* Known peripheral vascular disease that complicates cardiac catheterization

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No